BGIM
RNAM

Boussard & Gavaudan Investment Management’s Avidity Biosciences RNAM Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-328,204
Closed -$23.7M – 110
2025
Q4 		$23.7M Buy
+328,204
New +$21.2M 1.79% 15

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

Boussard & Gavaudan Investment Management's RNAM Position: Q1 2026 in Review

Boussard & Gavaudan Investment Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 328,204 shares — an estimated $23.7M sold.

Boussard & Gavaudan Investment Management first reported a position in RNAM in Q4 2025 and held it in 1 quarter. The position peaked at $23.7M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Boussard & Gavaudan Investment Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Boussard & Gavaudan Investment Management sold 328,204 Avidity Biosciences shares in Q1 2026, an estimated $23.7M.
  • Boussard & Gavaudan Investment Management first reported a position in Avidity Biosciences in Q4 2025 and held it in 1 quarter.
  • Boussard & Gavaudan Investment Management's Avidity Biosciences position peaked at $23.7M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q1 2026, filed 15 May 2026.